Recently, the Jiangsu Science and Technology Conference and the Provincial Science and Technology Awards Ceremony was held in Nanjing. The "Research and Development and Industrialization of Aumolertinib Mesilate, the Third-generation EGFR Lung Cancer Targeted Drug" project led by Hansoh Pharma won first prize among the Jiangsu Science and Technology Awards for 2023, making it the only pharmaceutical company to receive a top prize in this year's selection.
Aumolertinib Mesylate tablets (trade name: Ameile) are the first original third-generation EGFR-TKI developed by Hansoh Pharmaceutical in China. They have been approved in China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on prior EGFR-TKI therapy and are T790M mutation positive. They are also used for first-line treatment of adult patients with locally advanced or metastatic NSCLC who suffer from EGFR exon 19 deletion or exon 21 (L858R) substitution mutation-positive disease. This fills the medication gap in the domestic lung cancer sub-field. Both indications are now included in the national medical insurance catalog, significantly improving the accessibility and affordability of medication for patients.
In response to the challenges of drug resistance and brain metastasis in lung cancer treatment, Hansoh Pharma's R&D team creatively designed a novel drug molecule, Aumolertinib, which perfectly binds to the target protein EGFR. Aumolertinib irreversibly and highly selectively inhibits EGFR sensitive mutations and the T790M resistant mutation. By introducing a special lipophilic structure, it also offers significant clinical advantages to patients with brain metastasis. To date, Aumolertinib has received more than 40 authorized domestic and international invention patents, and the compound patent has won the "China Patent Gold Award" at the 24th session.
The Jiangsu Science and Technology Award, established by the Jiangsu Provincial People's Government, is the highest honor for innovation achievements within the province. Winning first prize is significant evidence of the company's technological innovation and R&D capabilities. Hansoh Pharma will continue to substantially boost its R&D investment and increasingly expedite the market launch of innovative drugs and treatment solutions to bring benefits to patients not only in China but also worldwide.
